CUMYL-INACA

The following information was compiled in June 2025 and is subject to change as new research is conducted and as new information becomes available:

Description: CUMYL-INACA is a synthetic cannabinoid precursor that can be used to produce 5F-CUMYL-PINACA, 4CN-CUMYL-BUTINACA, and other structurally related synthetic cannabinoids. Synthetic cannabinoid precursors (e.g., MDMB-INACA, ADB-INACA) began appearing after the implementation of a class-wide synthetic cannabinoid ban imposed by China in July 2021.^1-3 CUMYL-INACA was identified by our laboratory in April 2025 and confirmed after acquiring standard reference material.

Sample Source: Philadelphia Medical Examiner’s Office (Philadelphia, PA)

Sample Appearance: Blood specimen

Pharmacology: The activity and potency of CUMYL-INACA are unknown; however, based on structurally similar synthetic cannabinoid precursors, CUMYL-INACA is expected to be inactive or have low potency.

Toxicology: CUMYL-INACA has been detected in one toxicology case to date at the CFSRE.

Drug Materials: CUMYL-INACA has not been detected in drug materials to date at the CFSRE.

Demographics / Geographics: The toxicology specimen originated from Pennsylvania, and CUMYL-INACA was identified alongside other synthetic cannabinoids (e.g., 4CN-CUMYL-BUTINACA and 5F-ADB).

Legal Status: CUMYL-INACA is not currently a scheduled substance in the United States.

Class:

Cannabinoid

Appearance:

Blood

Formula:

C17H17N3O

MW:

279.3

[M+]:

279

[M+H]+:

280.1444

IUPAC:

N-(1-methyl-1-phenyl-ethyl)-1H-indazole-3-carboxamide

Report Date:

June 30, 2025